EFFICACY OF SARILUMAB PLUS CSDMARDS IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE TO ONE OR MORE THAN ONE PRIOR TNF INHIBITOR

被引：2
|
作者：
Genovese, M. C. [1 ]
Pinheiro, G. da R. C. [2 ]
Mangan, E. K. [3 ]
Lin, Y. [4 ]
van Adelsberg, J. [3 ]
van Hoogstraten, H. [4 ]
Thompson, D. [3 ]
Fleischmann, R. [5 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Univ Estado Rio De Janeiro, Discipline Rheumatol, Rio De Janeiro, Brazil
[3] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[4] Sanofi, Bridgewater, MA USA
[5] Metroplex Clin Res Ctr, Dallas, TX USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.4280
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0174
引用
收藏
页码：730 / 731
页数：2
相关论文
共 50 条
  • [1] EFFICACY OF SARILUMAB PLUS CSDMARDS IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE TO ONE OR MORE THAN ONE PRIOR TNF INHIBITOR
    Genovese, M.
    Pinheiro, G.
    Mangan, E.
    Lin, Y.
    Van Hoogstraten, H.
    Fleischmann, R.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 29 - 29
  • [2] Efficacy of Sarilumab Plus csDMARDs in Rheumatoid Arthritis Patients who had an Inadequate Response to One or More than One Prior TNF Inhibitor
    Genovese, Mark
    Pinheiro, Geraldo
    Mangan, Erin
    Lin, Yong
    van Adelsberg, Janet
    van Hoogstraten, Hubert
    Kimura, Toshio
    Fleischmann, Roy
    Fiore, Stefano
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 896 - 896
  • [3] EFFICACY OF SARILUMAB IN COMBINATION WITH CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITISAND INADEQUATE RESPONSE TO TNF INHIBITORS BY BASELINE LEVELS OF DISEASEACTIVITY
    Fleischmann, Roy
    van Hoogstraten, Hubert
    Jayawardena, Shyamalie
    Mangan, Erin K.
    Chings, Daniel
    Burmester, Gerd R.
    RHEUMATOLOGY, 2018, 57
  • [4] SUSTAINED EFFICACY IS ACHIEVED WITH MULTIPLE COURSES OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO ONE OR MORE TNF INHIBITORS
    Keystone, Edward
    Fleischmann, Roy
    Emery, Paul
    Dougados, Maxime
    Williams, Sarah
    Reynard, Mark
    RHEUMATOLOGY, 2011, 50 : 121 - 122
  • [5] MULTIPLE COURSES OF RITUXIMAB PRODUCE SUSTAINED EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO ONE OR MORE TNF INHIBITORS
    Keystone, E.
    Nash, P.
    Fleischmann, R.
    Emery, P.
    Dougados, M.
    Hall, S.
    Williams, S.
    Reynard, M.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 18 - 19
  • [6] Repeated treatment courses of rituximab in rheumatoid arthritis: Sustained efficacy in patients with an inadequate response to one or more TNF inhibitors
    Keystone, E.
    Fleischmann, R. M.
    Emery, P.
    Chubick, A.
    Dougadoss, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Hagerty, D.
    Coopers, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 432 - 432
  • [7] A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
    Inanc, Guezide Nevsun
    Terzioglu, Mustafa Ender
    Karabulut, Yusuf
    Yilmaz, Zevcet
    Tarhan, Emine Figen
    Enecik, Mehmet Emin
    Sahin, Ali
    Kucuk, Adem
    Ayan, Ayse
    Ozgen, Metin
    Karasu, Ugur
    Yolbas, Servet
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023, 53 (03) : 731 - 743
  • [8] Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNFα therapies
    Keystone, E. C.
    Burmester, G. R.
    Furie, R. A.
    Loveless, J. E.
    Emery, P.
    Isaacs, J.
    Jubb, R.
    Dawes, P.
    Cravets, M. W.
    Magrini, F.
    RHEUMATOLOGY, 2006, 45 : I46 - I47
  • [9] Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF-α therapies
    Keystone, EC
    Burmester, GR
    Furie, R
    Loveless, JE
    Emery, P
    Cravets, MW
    Magrini, F
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S141 - S142
  • [10] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
    Fleischmann, Roy
    van Hoogstraten, Hubert
    Jayawardena, Shyamalie
    Mangan, Erin K.
    Ching, Daniel
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345